PRNP and gastric cancer: In gastric cancer cells, in vitro administration of the Akt inhibitor LY294002 or Akt siRNAs leads to inhibition of PrPc-induced and CyclinD1-related CSC proliferation, G1/S phase transition, and multidrug drug resistance [25].